Real-world insights into the management of hemophilia A in Italy: treatment patterns and healthcare resource utilization.
Healthcare resource utilization
Hemophilia A
Monoclonal antibodies
Plasma-derived FVIII
Treatment patterns
Journal
Blood research
ISSN: 2287-979X
Titre abrégé: Blood Res
Pays: Switzerland
ID NLM: 101605247
Informations de publication
Date de publication:
08 Oct 2024
08 Oct 2024
Historique:
received:
15
04
2024
accepted:
23
09
2024
medline:
8
10
2024
pubmed:
8
10
2024
entrez:
8
10
2024
Statut:
epublish
Résumé
This real-world analysis described the Hemophilia A (HA) population in Italy, evaluating drug utilization and consumption of factor VIII (FVIII) products of patients under prophylaxis and on-demand therapy. From Jan-2017 to Jun-2022, male patients with HA were identified through prescriptions of FVIII products [extended half-life FVIII, standard half-life recombinant FVIII, and plasma-derived FVIII (EHL FVIII, SHL rFVIII, and pdFVIII, respectively)], or emicizumab or FVIII plus von Willebrand factor or HA-related hospitalization using administrative flows of Italian healthcare entities. Patients on treatment with FVIII products during 2021-2022 were stratified by treatment regimen (prophylaxis/on-demand). The mean annual consumption expressed in International Units (IU) of EHL FVIII and SHL FVIII in patients treated during 2021-2022 having at least 12-month follow-up were assessed. Among included HA patients, 145 (39.5%) received EHL FVIII and 222 (60.5%) SHL FVIII. Of 165 patients on prophylaxis, 105 (64%) received an EHL FVIII and 60 (36%) an SHL FVIII. The mean annual consumption of FVIII was 336,700 IU (median 319,000 IU) for EHL FVIII and 440,267 IU (median 360,500 IU) for SHL FVIII. Specifically, for patients on EHL FVIII, the most common drugs were efmoroctocog alfa (N = 51) and damoctocog alfa pegol (N = 50), followed by turoctocog alfa pegol (N = 25) and rurioctocog alfa pegol (N = 19). Of 702 HA patients initially treated with FVIII products, 74 (10.5%) switched to emicizumab during follow-up. These findings revealed an extensive use of EHL FVIII products, suggesting growing efforts from clinicians to optimize prophylactic strategies and achieve better bleeding protection.
Identifiants
pubmed: 39377876
doi: 10.1007/s44313-024-00034-6
pii: 10.1007/s44313-024-00034-6
doi:
Types de publication
Journal Article
Langues
eng
Pagination
30Informations de copyright
© 2024. The Author(s).
Références
Berntorp E, Fischer K, Hart DP, et al. Haemophilia. Nat Rev Dis Primers. 2021;7(1):45. https://doi.org/10.1038/s41572-021-00278-x .
doi: 10.1038/s41572-021-00278-x
pubmed: 34168126
Salen P, Babiker HM. Hemophilia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
World Federation of Hemophilia Report on the Annual Global Survey 2021. Available at: https://www1.wfh.org/publications/files/pdf-2324.pdf , last accessed 07 March, 2024
Castaman G, Matino D. Hemophilia A and B: molecular and clinical similarities and differences. Haematologica. 2019;104(9):1702–9. https://doi.org/10.3324/haematol.2019.221093 .
doi: 10.3324/haematol.2019.221093
pubmed: 31399527
pmcid: 6717582
Factor VIII Concentrates. Factor VIII/von Willebrand factor concentrates, factor IX concentrates, activated prothrombin complex concentrates. Transfus Med Hemother. 2009;36(6):409–18.
doi: 10.1159/000268062
Giampaolo A, Abbonizio F, Arcieri R, Hassan HJ. Italian registry of congenital bleeding disorders. J Clin Med. 2017;6(3):34. https://doi.org/10.3390/jcm6030034 .
doi: 10.3390/jcm6030034
pubmed: 28335488
pmcid: 5373003
Italian National Institute of Health (ISS). National Registry of congenital bleeding disorders. Report 2020. Available at: https://www.iss.it/documents/20126/6682486/22-38+web.pdf/fe31bd00-c203-c009-adc6-5e49620ba148?t=1678781150708 , last accessed 07 March 2024
Centers for Disease Control and Prevention. Hemophilia. Available at: https://www.cdc.gov/ncbddd/hemophilia/data.html , last accessed 07 March 2024
Mehta P, Reddivari AKR. Hemophilia. [Updated 2023 Jun 5]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551607/
Franchini M, Mannucci PM. Acquired haemophilia A: a 2013 update. Thromb Haemost. 2013;110(6):1114–20. https://doi.org/10.1160/TH13-05-0363 .
doi: 10.1160/TH13-05-0363
pubmed: 24008306
Aledort L, Mannucci PM, Schramm W, Tarantino M. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus. 2019;17(6):479–86. https://doi.org/10.2450/2019.0211-19 .
doi: 10.2450/2019.0211-19
pubmed: 31846611
pmcid: 6917528
Gomperts E, Lundblad R, Adamson R. The manufacturing process of recombinant factor VIII, recombinate. Transfus Med Rev. 1992;6(4):247–51. https://doi.org/10.1016/s0887-7963(92)70175-8 .
doi: 10.1016/s0887-7963(92)70175-8
pubmed: 1421823
Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020;105(3):545–53. https://doi.org/10.3324/haematol.2019.232132 .
doi: 10.3324/haematol.2019.232132
pubmed: 32060150
pmcid: 7049365
Cortesi PA, Giampaolo A, Abbonizio F, et al. Variability of treatment modalities and intensity in patients with severe haemophilia A on prophylaxis: Results from the Italian national registry. Eur J Haematol. 2021;107(4):408–15. https://doi.org/10.1111/ejh.13676 .
doi: 10.1111/ejh.13676
pubmed: 34110639
Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3
Peyvandi F, Kavakli K, El-Beshlawy A, Rangarajan S. Management of haemophilia a with inhibitors: a regional cross-talk. Haemophilia. 2022;28(6):950–61. https://doi.org/10.1111/hae.14638 .
doi: 10.1111/hae.14638
pubmed: 35868021
pmcid: 9796719
FDA Approves Hemlibra (emicizumab-kxwh) for Hemophilia A with Inhibitors. Available at: https://www.drugs.com/newdrugs/fda-approves-hemlibra-emicizumab-kxwh-hemophilia-inhibitors-4639.html , last accessed 07 March 2024
European Medicines Agency (EMA). Hemlibra (emicizumab). Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/hemlibra , last accessed 07 March 2024
Agenzia Italiana del Farmac (AIFA). Determina 21 febbraio 2020 Regime di rimborsabilita' e prezzo a seguito di nuove indicazioni terapeutiche del medicinale per uso umano «Hemlibra». (Determina n. 206/2020).). Available at: https://www.gazzettaufficiale.it/eli/id/2020/03/18/20A01588/SG , last accessed 07 March 2024
Kiialainen A, Niggli M, Kempton CL, et al. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study. Haemophilia. 2022;28(6):1033–43. https://doi.org/10.1111/hae.14642 .
doi: 10.1111/hae.14642
pubmed: 35905294
pmcid: 9796488
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83. https://doi.org/10.1016/0021-9681(87)90171-8 .
doi: 10.1016/0021-9681(87)90171-8
pubmed: 3558716
Kempton CL, Makris M, Holme PA. Management of comorbidities in haemophilia. Haemophilia. 2021;27(Suppl 3):37–45. https://doi.org/10.1111/hae.14013 .
doi: 10.1111/hae.14013
pubmed: 32476243
Versloot O, Iserman E, Chelle P, Germini F, Edginton AN, Schutgens REG, Iorio A, Fischer K, Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (IPSG). Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. J Thromb Haemost. 2021;19(8):1896–906. https://doi.org/10.1111/jth.15395 .
doi: 10.1111/jth.15395
pubmed: 34013558
pmcid: 8361743
Cortesi PA, Di Minno G, Zanon E, et al. Real-world clinical outcomes and replacement factor VIII consumption in patients with Haemophilia A in Italy: a comparison between prophylaxis pre and post Octocog Alfa (BAY 81–8973). J Clin Med. 2022;11(12):3434. https://doi.org/10.3390/jcm11123434 .
doi: 10.3390/jcm11123434
pubmed: 35743504
pmcid: 9224869
Nolan B, Mahlangu J, Pabinger I, et al. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia. 2020;26(3):494–502. https://doi.org/10.1111/hae.13953 .
doi: 10.1111/hae.13953
pubmed: 32227570
pmcid: 7384031
Blatný J, Nielsen EM, Reitzel SB, et al. Real-world evidence on efmoroctocog alfa in patients with haemophilia A: A systematic literature review of treatment experience in Europe. Haemophilia. 2023;29(4):963–74. https://doi.org/10.1111/hae.14797 .
doi: 10.1111/hae.14797
pubmed: 37243934
Frampton JE. Efmoroctocog Alfa: a review in Haemophilia A. Drugs. 2021;81(17):2035–46. https://doi.org/10.1007/s40265-021-01615-w . Epub 2021 Nov 7. Erratum in: Drugs. 2022 Jan;82(1):95.
doi: 10.1007/s40265-021-01615-w
pubmed: 34743314
pmcid: 8636404
Escobar M, Agrawal N, Chatterjee S, et al. Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors. J Med Econ. 2023;26(1):574–80. https://doi.org/10.1080/13696998.2023.2196922 .
doi: 10.1080/13696998.2023.2196922
pubmed: 36989380
Cafuir L, Estrin A, Chen E, et al. Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors. J Med Econ. 2022;25(1):984–92. https://doi.org/10.1080/13696998.2022.2102779 .
doi: 10.1080/13696998.2022.2102779
pubmed: 35848992
Italian Association of Haemophilia Centres (AICE). Gestione del paziente con Emofilia A grave senza inibitore in profilassi con Emicizumab con particolare riferimento alle condizioni di emergenza/urgenza. Available at: https://aiceonline.org/wp-content/uploads/2020/10/Emicizuab-non-inibitore-settembre-2020.pdf , last accessed 07 March 2024